Scientists investigate why some stomach cancers shrink with immunotherapy and others Don't
NCT ID NCT07259473
First seen Jan 05, 2026 · Last updated Apr 26, 2026 · Updated 20 times
Summary
This study looks at a specific type of stomach cancer (dMMR/MSI-H) that often responds well to immunotherapy, but about half of patients do not benefit. Researchers will treat 15 people with immunotherapy before surgery to see who has a complete response and study why some tumors resist treatment. The goal is to find clues that could help more patients in the future.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IMMUNOTHERAPY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.